Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

December 02, 2024

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

December 02, 2024

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

November 19, 2024

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

October 24, 2024

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

October 17, 2024

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

September 18, 2024

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

August 06, 2024

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

July 30, 2024

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

July 30, 2024

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

July 23, 2024

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

July 23, 2024

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

July 08, 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

May 30, 2024

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

May 16, 2024

Seeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.

April 16, 2024

Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.

March 26, 2024

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

March 19, 2024

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

March 19, 2024

Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.

March 13, 2024

A consequence of the Alabama Supreme Court’s in vitro fertilization ruling is an unacceptably high risk of infertility for patients with cancer.

March 12, 2024

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.